Amyris Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This Amyris Balanced Scorecard Analysis gives you a structured view of the company's financial, customer, internal process, and learning and growth priorities. The page already shows a real preview of the actual deliverable, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Cash Discipline
Cash discipline is the key lens for Amyris after its 2023 Chapter 11 filing, because the real test is not sales growth but whether cash burn is shrinking. The company sold key brands in bankruptcy, including Costa Brazil for $5 million and 4U by Tia for $4 million, so each month of liquidity mattered. A Balanced Scorecard helps investors judge if remaining value is being preserved or destroyed, based on burn rate, working capital, and cash runway.
IP Value
Amyris's most durable asset is its proprietary strain engineering and fermentation platform, not its old consumer brand story. In a balanced scorecard, IP value helps track patent use, know-how reuse, and licensing potential, which matters more when core assets are intangible and repeatable. That lens also makes it easier to spot whether the technology base can still create cash from partnerships, even after Chapter 11 reshaped the business.
Yield Economics
Yield economics is the gatekeeper for Amyris: if fermentation yield, titer, and downstream recovery do not fall, plant-sugar inputs stay too costly for scalable ingredients. A Balanced Scorecard links R&D wins to unit cost, because Amyris's last public filing showed 2022 revenue of "$270 million" and a net loss of "$1.1 billion," so small process gains mattered. No public 2025 fiscal data is available after its Chapter 11 collapse.
Market Fit
Amyris spans flavors, fragrances, cosmetics, nutraceuticals, and pharmaceuticals, so one strong line can hide weak demand in another. A Balanced Scorecard makes that mix clearer by splitting customer traction from pilot-stage adoption, instead of reading all sales as one signal. That matters when early-stage launches still sit below scale, while mature lines carry the P&L. It helps show where fit is real and where the product still needs proof.
Partner Control
Partner control helps Amyris track customer qualification, regulatory milestones, and scale-up commits with each partner, so weak handoffs show up early. In a B2B ingredient model, one missed spec or approval can stall shipments for quarters, and that can push out revenue recognition and cash flow. This scorecard keeps technical, legal, and sales teams aligned on the exact gate a partner must clear before volume ramps.
Balanced Scorecard Reveals Amyris's Recovery Signals After Chapter 11
Amyris's Balanced Scorecard helps isolate where value can still be preserved after Chapter 11 by tracking cash burn, IP reuse, and partner execution. It also ties process gains to economics, which mattered when 2022 revenue was $270 million and net loss was $1.1 billion. With no 2025 fiscal filing, this lens is the clearest way to judge recovery signals.
| Benefit | Why it matters |
|---|---|
| Cash control | Tracks burn and runway |
| IP value | Checks reuse and licensing |
| Partner execution | Flags scale-up delays |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Distress Skew
Amyris's distress skew is severe after Chapter 11 in August 2023 and brand divestitures, because the balanced scorecard can miss the real question: how much value is left to recover. With about $1.4 billion in assets and $1.9 billion in liabilities at filing, revenue, market share, and customer growth matter less than liquidation proceeds and debt settlement. In this case, the classic four perspectives can overstate going-concern value and understate recovery risk.
Noisy Metrics
Amyris's KPI line can look erratic because fermentation trials, formulation changes, and tiny production runs shift yield and cost fast. In 2022, Amyris reported $268.8 million in revenue and a $1.3 billion net loss, so quarter-to-quarter swings already sat inside a very unstable base. That makes a bad 3-month read easy to confuse with a real process fault, when it may just be a scale-up miss.
Long Lag
Long lag is a real flaw in Amyris Balanced Scorecard Analysis because a better strain or process can take months before lower cost of goods sold shows up. Amyris filed Chapter 11 in 2023 after a 2022 net loss of about $1.3 billion, so cash stress hit far faster than process gains could be seen. That delay makes the scorecard slow to warn management when a single quarter can already change the cash picture.
Data Gaps
Amyris's restructuring, asset sales, and spotty disclosures make clean benchmarking hard. With no steady 2025-style reporting on yields, gross margin, inventory turns, or customer conversion, the Balanced Scorecard leans too much on narrative. That weakens year-over-year comparison and masks whether unit economics are improving or just being reshaped by bankruptcy-linked moves.
In practice, the data gap means even simple trend checks can mislead. Any scorecard read should treat the company's reported numbers as incomplete, not stable operating signals.
Metric Gaming
Metric gaming is a real risk at Amyris: a team can push yield or unit cost down, but still hurt commercial flexibility, working capital, or mix. That matters more in a multi-ingredient portfolio, where one local gain can lower total enterprise value; Amyris filed for Chapter 11 in 2023, so there is no 2025 fiscal data to anchor a full scorecard.
So, a balanced scorecard needs guardrails that track margin, cash conversion, and customer service together, not one plant KPI in isolation.
Amyris Scorecard Breaks Under Chapter 11 Stress
Amyris's Balanced Scorecard is weak because there is no 2025 fiscal data after Chapter 11, so trend checks and peer comparisons break down. The most useful numbers are still the filing-era stress points: about $1.4 billion in assets and $1.9 billion in liabilities, plus 2022 revenue of $268.8 million against a $1.3 billion net loss.
| Metric | Latest hard data | Why it hurts the scorecard |
|---|---|---|
| Assets | $1.4B | Recovery focus replaces growth |
| Liabilities | $1.9B | Solvency distorts KPI meaning |
| Revenue | $268.8M | Base is too unstable |
| Net loss | $1.3B | Cash stress outruns operating gains |
Get Your Copy
Amyris Reference Sources
This is the actual Amyris Balanced Scorecard analysis document you'll receive after purchase – no surprises, just the real report.
The preview below is taken directly from the full file, so what you see now is what you'll download in full.
Purchase unlocks the complete, detailed Balanced Scorecard analysis, ready for immediate use.
Frequently Asked Questions
It measures whether Amyris can turn its fermentation platform into recoverable value. The most useful indicators are the 4 scorecard perspectives, but the practical watchlist is smaller: cash burn, gross margin, and fermentation yield. Because the company entered Chapter 11 in 2023, the scorecard is best used to judge residual asset quality, not just growth ambition.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.